{"id":3928,"date":"2026-10-27T09:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3928"},"modified":"2026-10-27T20:53:05","modified_gmt":"2026-10-28T00:53:05","slug":"aml-antigen-study-revises-u5-surface-binding-model","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3928","title":{"rendered":"AML Antigen Study Revises U5 Surface Binding Model"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Amsterdam UMC (academic)<\/p>\n

Event Type<\/strong><\/p>\n

Peer-reviewed publication<\/p>\n

Modality<\/strong><\/p>\n

Target validation (antibody and CAR binder design)<\/p>\n

Asset<\/strong><\/p>\n

U5 snRNP200 surface antigen model<\/p>\n

Target<\/strong><\/p>\n

U5 snRNP200; Fc\u03b3RIIa; heparan sulfate<\/p>\n

Disease Area<\/strong><\/p>\n

Acute myeloid leukemia<\/p>\n

Summary<\/h4>\n

An online-first, peer-reviewed Scientific Reports paper dated 27 October revises how the atypical AML surface antigen U5 snRNP200 is displayed and recognized. Its finding affects antibody and CAR design, but is mechanistic preclinical evidence, not a patient treatment result.<\/p>\n

The investigators found U5 snRNP200 on ovarian cancer cells without Fc\u03b3RIIa and found that CRISPR knockout of Fc\u03b3RIIa in AML-derived THP-1 cells did not remove U5 surface expression. Fc\u03b3R expression nevertheless increased intact-antibody binding, whereas Fab or F(ab\u2019)2, Fc-silent formats and Fc\u03b3R blockade reduced measured binding. Lower heparan-sulfate expression decreased U5 surface signal. The authors propose heparan-sulfate tethering rather than obligatory Fc\u03b3RIIa-dependent display. The paper identifies a previously reported approximate 50% AML-blast expression prevalence; that is background, not a new clinical estimate.<\/p>\n

Deep Analysis<\/h4>\n

The key translational point is assay interpretation: an antibody can appear to recognize a tumor surface target more strongly because of Fc receptor co-binding. Decoupling antigen localization from Fc-mediated avidity should improve selection of Fc-silent antibodies and CAR binders. Yet target density on primary leukemia stem cells, normal HSCs and nonhematopoietic tissues remains crucial. Heparan-sulfate anchoring could vary by tissue and treatment state, and a noncanonical surface RNA-binding protein may be shed or internalized unpredictably. The study provides no human efficacy, marrow biodistribution, cytokine-release, manufacturing or durability evidence. Earlier U5 CAR-T and antibody reports provide therapeutic context; the new paper specifically changes the surface-mechanism model.<\/p>\n

Company and Product Background<\/h4>\n

U5 snRNP200 is normally an intracellular RNA-splicing helicase but has been reported at the AML-cell surface. Researchers have explored antibodies and CAR-T cells against it as a route around shared myeloid antigens.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> U5 remains a feasible AML target despite loss of the proposed Fc\u03b3RIIa tether; knockout and cell-line data support this.<\/li>\n
  • Interpretation B:<\/strong> observed binding partly reflects Fc-dependent assay artifact, reducing confidence in therapeutic selectivity; fragment and blocking experiments support that caution.<\/li>\n
  • Upgrade<\/strong> with quantitative primary AML\/HSC antigen density and Fc-independent in-vivo killing. Downgrade<\/strong> with normal-tissue binding or antigen loss. Falsification:<\/strong> independent assays cannot reproduce surface U5 without Fc receptors.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the paper is valuable target-validation refinement and suggests concrete assay controls; it does not move U5-directed therapy into clinical readiness.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 3 of 5. Signal Direction: mixed for target development. Confidence in Facts: moderate to high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    An online-first, peer-reviewed Scientific Reports paper dated 27 October revises how the atypical AML surface antigen U5 snRNP200 is displayed and recognized. Its finding affects antibody and CAR design, but is mechanistic preclinical evidence,…<\/p>\n","protected":false},"author":1,"featured_media":3938,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,1232,1189,1231,1230],"class_list":["post-3928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-amsterdam-umc","tag-car-t-2","tag-scientific-reports","tag-u5-snrnp200"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3928"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3928\/revisions"}],"predecessor-version":[{"id":3948,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3928\/revisions\/3948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3938"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}